GlassScriptPhysician profile
Andrew Iskandar
NPI 1609302017
$1,419.85
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $125 · 2023: $800 · 2024: $92.33 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $638 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $637.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $540.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $618.00 | 2023 | Cabometyx |
| Incyte Corporation | $137.18 | 2022-2025 | Zynyz |
| Novo Nordisk INC | $117.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Caris Mpi, INC. | $98.25 | 2025 | Mi Cancer Seek |
| Janssen Scientific Affairs, LLC | $91.93 | 2023 | Tecvayli, Darzalex, Carvykti |
| Alexion Pharmaceuticals, INC. | $89.75 | 2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $40.28 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $34.34 | 2024-2025 | Lynparza, Enhertu |
| Daiichi Sankyo INC. | $23.76 | 2025 | Enhertu |
| Astellas Pharma US INC | $20.20 | 2025 | Xtandi |
| Janssen Biotech, INC. | $18.40 | 2024 | Tecvayli |
| Pharmacosmos Therapeutics INC. | $17.72 | 2024 | Monoferric |
| Morphosys, US INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Iskandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.